Vaccinated animals demonstrated stronger acute viral pulldown than controls, but a trend for higher acute viremia was observed in the DM؉VLP group, likely due to a slower recall of Gag-specific CD8 T cells. Our findings support immunization with VLPs containing trimeric Env as a strategy to augment protective antibody but underscore the need for optimal engagement of CD8 T cells to achieve robust early viral control.
IMPORTANCEThe development of an effective HIV vaccine remains a global necessity for preventing HIV infection and reducing the burden of AIDS. While this goal represents a formidable challenge, the modest efficacy of the RV144 trial indicates that multicomponent vaccination regimens that elicit both cellular and humoral immune responses can prevent HIV infection in humans. However, whether protein immunizations synergize with DNA prime-viral vector boosts to enhance cellular and humoral immune responses remains poorly understood. We addressed this question in a nonhuman primate model, and our findings show benefit for sequential protein immunization combined with a potent adjuvant in boosting antibody titers induced by a preceding DNA/MVA immunization. This promising strategy can be further developed to enhance neutralizing antibody responses and boost CD8 T cells to provide robust protection and viral control. W ith over 2.5 million new human immunodeficiency virus (HIV) infections per year, the majority in resource-poor countries with limited access to antiretroviral therapy, an effective HIV vaccine continues to remain among the most promising and safe strategies for preventing infection and reducing the burden of AIDS (1). To date, there have been six HIV vaccine efficacy trials that tested four different vaccine concepts. Only the RV144 trial showed a modest level of efficacy (2), and immune correlate analyses have yielded critical insights into immune determinants of vaccine-induced protection against HIV (3). Together with experimental data from rhesus models of HIV, these data underscore two key elements of vaccine efficacy: the induction of robust and long-lasting antibodies (Abs) against the envelope glycoprotein (Env) with potent neutralizing and effector functions to prevent the acquisition of infection and the induction of cytolytic T cell responses against Gag proteins for controlling viral replication in the event of infection (4, 5). Consequently, vaccine strategies that Citation Iyer SS, Gangadhara S, Victor B, Shen X, Chen X, Nabi R, Kasturi SP, Sabula MJ, Labranche CC, Reddy PJ, Tomaras GD, Montefiori DC, Moss B, Spearman P, Pulendran B, Kozlowski PA, Amara RR. 2016. Virus-like particles displaying trimeric simian immunodeficiency virus (SIV) envelope gp160 enhance the breadth of DNA/modified vaccinia virus Ankara SIV vaccine-induced antibody responses in rhesus macaques. J Virol 90:8842-8854.